Drug intelligence / Profile preview

REGN14284

Development stage: Phase 1
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

REGN14284 is an investigational drug developed by Regeneron Pharmaceuticals for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is being studied as a SARS-CoV-2 antigen inhibitor, with both intravenous and subcutaneous routes of administration under evaluation. The primary focus in clinical trials has been to assess its safety and tolerability in healthy participants. The highest reported development phase is Phase 1.

Targets

Spike-ACE2 PPI (SARS-CoV-2 spike–ACE2 interface)RBD (SARS-CoV-2 spike receptor-binding domain)SARS-CoV-2 spike glycoprotein receptor-binding domain – lateral allosteric epitope

Beyond the preview

Go deeper on REGN14284.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGN14284.

Explore the full profile